Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) in a research note issued to investors on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.

Shares of NASDAQ CYCC opened at $2.05 on Monday. Cyclacel Pharmaceuticals has a twelve month low of $1.96 and a twelve month high of $7.95. The stock’s 50 day moving average price is $3.19 and its 200-day moving average price is $3.88. The company has a market capitalization of $20.49 million, a PE ratio of -0.96 and a beta of 1.21.

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) last announced its earnings results on Monday, March 28th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.17. During the same period in the previous year, the company posted ($1.34) earnings per share. Research analysts expect that Cyclacel Pharmaceuticals will post -3.46 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. Tri Locum Partners LP lifted its stake in Cyclacel Pharmaceuticals by 66.9% in the third quarter. Tri Locum Partners LP now owns 522,943 shares of the biotechnology company’s stock valued at $2,756,000 after purchasing an additional 209,612 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in Cyclacel Pharmaceuticals by 5.3% in the third quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biotechnology company’s stock valued at $2,108,000 after purchasing an additional 20,000 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its stake in Cyclacel Pharmaceuticals by 210.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 322,373 shares of the biotechnology company’s stock valued at $1,254,000 after purchasing an additional 218,448 shares during the last quarter. Two Sigma Advisers LP lifted its stake in Cyclacel Pharmaceuticals by 929.7% in the third quarter. Two Sigma Advisers LP now owns 121,500 shares of the biotechnology company’s stock valued at $640,000 after purchasing an additional 109,700 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Cyclacel Pharmaceuticals by 21.3% in the second quarter. Morgan Stanley now owns 121,275 shares of the biotechnology company’s stock valued at $718,000 after purchasing an additional 21,275 shares during the last quarter. Institutional investors and hedge funds own 37.00% of the company’s stock.

About Cyclacel Pharmaceuticals (Get Rating)

Cyclacel Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.

Further Reading